SCHEMBL1979977

SCHEMBL1979977

CC1(C)NC(=O)N(c2ccc(Oc3ccc(C#N)cc3C3CC3)nc2)C1=O

nearest known ligand 0.41

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
AR P10275 7/20 0.41
HSD11B1 P28845 5/20 0.38
HSD11B2 P80365 3/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.37
CYP11B2 P19099 1/20 0.36
PTH1R Q03431 1/20 0.34
ROCK2 O75116 1/20 0.34
EGLN1 Q9GZT9 1/20 0.33
EZH2 Q15910 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30939574 1.00 AR (0.41) ARHSD11B1HSD11B2PTGDR2CYP11B2
SCHEMBL30939616 0.89 HSD11B1 (0.38) ARHSD11B1HSD11B2PTGDR2CYP11B2
SCHEMBL1979096 0.89 HSD11B1 (0.38) ARHSD11B1HSD11B2PTGDR2CYP11B2
SCHEMBL18952995 0.89 PTGDR2 (0.38) ARHSD11B1HSD11B2PTGDR2CYP11B2
SCHEMBL13720513 0.85 AR (0.44) ARHSD11B1HSD11B2
SCHEMBL1984809 0.84 AR (0.43) ARHSD11B1HSD11B2
SCHEMBL1979175 0.83 AR (0.44) ARHSD11B1HSD11B2
SCHEMBL1978546 0.82 AR (0.46) AR
SCHEMBL30939663 0.82 AR (0.46) AR
SCHEMBL1980831 0.82 AR (0.53) AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 US claimed
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-11-29 US claimed
US-10058551-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2018-08-28 US claimed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 US claimed
US-9849131-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2017-12-26 US claimed
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2017-03-09 US claimed
EP-2509961-B1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LTD (GB) 2016-03-09 EP claimed
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2016-03-03 US claimed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 US claimed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 US claimed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 EP claimed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 WO claimed
US-20250017925-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN AUTIFONY THERAPEUTICS LIMITED (GB) 2025-01-16 US disclosed
CN-118267386-A Modulators of KV3 channels for the treatment of pain 奥提芙尼治疗学有限公司 2024-07-02 CN disclosed
CN-108472288-B Modulators of KV3 channels for the treatment of pain 奥提芙尼治疗学有限公司 2024-05-28 CN disclosed
US-11944623-B2 Modulators of Kv3 channels to treat pain AUTIFONY THERAPEUTICS LIMITED (GB) 2024-04-02 US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 US disclosed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 EP disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 WO disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 AR 4780/4885HSD11B1 1850/4885HSD11B2 1636/4885
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 AR 4780/4885HSD11B1 1850/4885HSD11B2 1636/4885
US-10632118-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 AR 4780/4885HSD11B1 1850/4885HSD11B2 1636/4885
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 AR 4780/4885HSD11B1 1850/4885HSD11B2 1636/4885
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 AR 4780/4885HSD11B1 1850/4885HSD11B2 1636/4885
US-10058551-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 AR 4780/4885HSD11B1 1850/4885HSD11B2 1636/4885
US-11944623-B2 Modulators of Kv3 channels to treat pain KCNN3, KCNA3, KCND3 AR 4434/4885HSD11B1 3432/4885HSD11B2 3739/4885
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 AR 4638/4885HSD11B1 1875/4885HSD11B2 1758/4885
US-20250017925-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN KCNN3, KCNA3, KCND3 AR 4434/4885HSD11B1 3432/4885HSD11B2 3739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.